Announcements

    Drinks

      Instrument data
      Issuer
      Senority
      Senior Unsecured
      Currency
      EUR
      ISIN
      FR0013505112
      Coupon percent
      1.5%
      Coupon type
      Fixed:Plain Vanilla Fixed Coupon
      Instrument volume
      750,000,000
      Maturity date
      01/04/2030
      -
      AA Outlook: None
      AA Outlook: None
      Latest change
      Affirmed
      06/12/2024
      General information
      Rating
      Public
      Solicited
      With issuer participation
      UK endorsed
      EU Rated
      Azza Chammem Lead analyst
      Sebastian Zank Committee chair
      Scope affirms Sanofi’s AA/Stable issuer rating

      6/12/2024 Rating announcement EN

      Scope affirms Sanofi’s AA/Stable issuer rating

      The affirmation reflects Sanofi’s robust operating performance, driven by a continued increase in Dupixent sales and low indebtedness.

      Scope affirms Sanofi’s AA/Stable issuer rating

      11/4/2023 Rating announcement EN

      Scope affirms Sanofi’s AA/Stable issuer rating

      The affirmation reflects Sanofi’s resilient operating performance and low indebtedness.

      Scope affirms Sanofi’s AA issuer rating and revises the Outlook to Stable from Positive.

      20/4/2022 Rating announcement EN

      Scope affirms Sanofi’s AA issuer rating and revises the Outlook to Stable from Positive.

      The rating action reflects our view of delayed deleveraging against our previous expectations.

      Scope Ratings affirms Sanofi's AA issuer rating and changes the Outlook to Positive

      19/5/2021 Rating announcement EN

      Scope Ratings affirms Sanofi's AA issuer rating and changes the Outlook to Positive

      The ratings continue to reflect Sanofi's improved positioning in growth sectors like rare diseases and immunology as well as management's credit-supportive financial policy.

      Scope affirms AA/Stable issuer rating on Sanofi

      9/9/2020 Rating announcement EN

      Scope affirms AA/Stable issuer rating on Sanofi

      The ratings reflect the company's leading position in a number of therapeutic areas as well as recent success with newly approved drugs contributing to a good credit metrics recovery in 2019, which Scope expects to continue.

      Scope affirms Sanofi at AA, Stable Outlook

      19/9/2019 Rating announcement EN

      Scope affirms Sanofi at AA, Stable Outlook

      The rating reflects Sanofi's leading positions in vaccines, anti-diabetics and rare diseases within a credit-supportive underlying industry as well as the strong recovery for credit metrics expected by rating agency.

      Date Title